Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00054212" target="_blank" >RIV/00216224:14110/11:00054212 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209805:_____/11:#0000156

Výsledek na webu

<a href="http://dx.doi.org/10.4021/wjon385w" target="_blank" >http://dx.doi.org/10.4021/wjon385w</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4021/wjon385w" target="_blank" >10.4021/wjon385w</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

Popis výsledku v původním jazyce

Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease- free interval. The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women ofsimilar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology. The AgRP plasma levels were signifi cantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women; onthe contrary, the AgRP plasma levels were highest in non-obese cancer survivors.

Název v anglickém jazyce

Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

Popis výsledku anglicky

Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease- free interval. The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women ofsimilar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology. The AgRP plasma levels were signifi cantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women; onthe contrary, the AgRP plasma levels were highest in non-obese cancer survivors.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED2.1.00%2F03.0101" target="_blank" >ED2.1.00/03.0101: Regionální centrum aplikované molekulární onkologie (RECAMO)</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World Journal of Oncology

ISSN

1920-4531

e-ISSN

—

Svazek periodika

2

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

6

Strana od-do

232-237

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—